FDA patience runs out for ProAmatine proof; Tauzin: PhRMA re-orientation ill advised;

> The FDA, wondering where the post-approval studies are that it required in 1996 as part of an accelerated approval, now proposes withdrawing that approval for ProAmatine (midodrine hydrochloride), used to treat a low blood pressure condition. Release

> Billy Tauzin advises new PhRMA leadership not to try turning back the "big ship" that he took "a long time turning." Item

> Mathi Senapathi has joined Radient as manufacturing director, responsible for the Onko-Sure in vitro diagnostic cancer test kits. Release

> Africa's Aspen Pharmacare will buy Australia's Sigma's pharmaceutical division, which manufactures generic and branded drugs. Article (sub. req.)

> EnWave is testing a multiple-vial prototype of its dehydration technology for standard industry serum vials containing vaccines, injectable drugs, analytical enzymes, diagnostic reagents, antibodies and other biological materials. Release